foxo4-dri senolytic or senomorphic FOXO4-DRI: Human Trial Status, Cancer Research & Data Molecular modelling of the FOXO4-TP53
Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases FOXO4 DRI Peptide for Cellular Senescence and Anti Aging Research Class II senolytics inhibit survival pathways elicited by senescent Download Scientific Diagram The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity.
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10


